In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176).
Read more about Cancerous Battle: Novartis and NATCO clash over EltrombopagTag: cancer drug
Patent Infringement Claim on Cancer Treatment Drug
The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim construction and the approach to pharmaceutical patent disputes across multiple European jurisdictions.
Read more about Patent Infringement Claim on Cancer Treatment Drug